[Latest] Global Cancer Vaccine Market Size Envisioned at USD 18.03 Billion by 2030, Increasing a CAGR of 11.6% | Healthcare Revolution
11 sept. 2023 07h42 HE
|
Zion Market Research
NEW YORK, United States, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Cancer Vaccine Market By Type (Preventive Cancer Vaccines, And...
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
07 août 2023 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on investigational cancer immunotherapy PV-10 (rose bengal...
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
25 mai 2023 17h00 HE
|
Evaxion Biotech
Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccinesPreclinically validated for both DNA and mRNA vaccines, and ready for clinical...
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
28 mars 2023 07h46 HE
|
Evaxion Biotech
New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023Phase 2b clinical trial reduced in size and expected to reach interim data...
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
14 mars 2023 16h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound
10 févr. 2023 07h35 HE
|
Sunshine Biopharma Inc.
MONTREAL, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas...
Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer
25 janv. 2023 21h15 HE
|
Cell BioEngines, Inc.
BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors,...
BioNTech kündigt strategische Partnerschaft mit der Regierung des Vereinigten Königreichs an, um bis 2030 bis zu 10.000 Patientinnen und Patienten mit personalisierten mRNA-Krebsimmuntherapien zu behandeln
05 janv. 2023 19h01 HE
|
BioNTech SE
Die mehrjährige Vereinbarung fokussiert sich auf drei strategische Bereiche: Krebsimmuntherapien, Impfstoffe gegen Infektionskrankheiten und weitere Expansion von BioNTech im Vereinigten...
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
05 janv. 2023 19h01 HE
|
BioNTech SE
Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech’s footprint in the UKBioNTech aims to design and roll out...
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
03 janv. 2023 07h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...